SCHEMBL17325898

SCHEMBL17325898

COc1cnc2c(=O)[nH]cnc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.49
▸ HPGD P15428 4/20 0.49
▸ XDH P47989 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ SRC P12931 1/20 0.42
▸ ADORA3 P0DMS8 2/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ LMNA P02545 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18779094 0.77 KDM4E (0.48) ALDH1A1HPGDXDHKDM4EHSD17B10
SCHEMBL21339749 0.73 SRC (0.52) ALDH1A1HPGDXDHKDM4EHSD17B10
SCHEMBL17954346 0.72 MAPK1 (0.36) ALDH1A1HPGDXDHKDM4EHTT
SCHEMBL349092 0.71 SRC (0.50) ALDH1A1HPGDXDHKDM4EHSD17B10
SCHEMBL13187699 0.71 HPGD (0.47) ALDH1A1HPGDXDHKDM4EHSD17B10
SCHEMBL17164123 0.71 SRC (0.43) ALDH1A1HPGDXDHSRCKMT2A
SCHEMBL14358306 0.70 ADORA3 (0.46) ALDH1A1HPGDXDHKDM4ESRC
SCHEMBL29631083 0.70 ADORA3 (0.46) ALDH1A1HPGDXDHKDM4ESRC
SCHEMBL11103935 0.68 NOS1 (0.56) ALDH1A1HPGDXDHKDM4EHSD17B10
SCHEMBL24629159 0.67 ALDH1A1 (0.52) ALDH1A1HPGDXDHKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148996-B1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2021-05-05 — — EP disclosed
US-9732088-B2 C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2017-08-15 — — US disclosed
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-04-27 — — US disclosed
WO-2015187437-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2015-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE2, BACE1, APP ALDH1A1 1120/4885HPGD 2665/4885XDH 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback